US Patent 11,185,541: Scope, Claims, Expiration, and Patent Landscape for Olanzapine-Samidorphan
US Patent No. 11,185,541 protects methods of treating schizophrenia using a daily 10 mg dose of samidorphan, administered with olanzapine either in a single pharmaceutical composition or as separate concurrent therapy. The patent is directed to the therapeutic use of the olanzapine-samidorphan combination, not to olanzapine alone or to samidorphan as a standalone molecule.
The claims are commercially relevant to Lybalvi, Alkermes’ fixed-dose combination of olanzapine and samidorphan. The patent’s principal enforcement risk concerns generic or follow-on products that contain 10 mg of samidorphan, or its pharmaceutically acceptable salt, and are labeled for schizophrenia treatment.
What drug and active ingredients does US 11,185,541 cover?
The compound represented by the omitted structure in the supplied claims is samidorphan. The patent covers samidorphan administered with olanzapine for schizophrenia.
| Element |
Covered subject matter |
| Active compound |
Samidorphan |
| Dose |
10 mg, expressly based on free-base weight in claims 7 and 10 |
| Companion drug |
Olanzapine |
| Route |
Oral |
| Frequency |
Daily |
| Disease |
Schizophrenia |
| Dosage forms |
Broadly, pharmaceutical compositions; tablets are expressly claimed |
| Salt forms |
Pharmaceutically acceptable salts of samidorphan |
| Formulation excipients |
Broadly claimed; lactose and magnesium stearate are expressly recited in dependent claims |
| Commercial product most directly implicated |
Lybalvi |
Lybalvi tablets contain olanzapine and samidorphan in several strengths, including 5 mg/10 mg, 10 mg/10 mg, 15 mg/10 mg, and 20 mg/10 mg olanzapine/samidorphan presentations. The protected feature is the fixed 10 mg samidorphan dose, not a single specific olanzapine strength. [2]
What are the independent claims in US Patent 11,185,541?
The patent has three principal independent claim groups: claim 1, claim 7, and claim 10.
Claim 1: Fixed-dose pharmaceutical composition
Claim 1 covers:
- A patient with schizophrenia;
- Daily oral administration;
- A pharmaceutical composition;
- Olanzapine;
- 10 mg of samidorphan or a pharmaceutically acceptable salt;
- A pharmaceutically acceptable excipient.
This is the most direct fixed-combination claim. It is broad as to the amount of olanzapine because the claim does not specify a particular olanzapine dose. It is also broad as to formulation because the composition is not limited to a tablet, lactose, magnesium stearate, or any particular manufacturing process.
A product may fall within claim 1 if it contains olanzapine and 10 mg of samidorphan in a single oral composition and is administered daily to treat schizophrenia.
Claim 7: Separate or combined administration
Claim 7 covers a treatment method in which:
- 10 mg of samidorphan, calculated on a free-base basis, is administered daily; and
- olanzapine is administered daily as the antipsychotic.
Unlike claim 1, claim 7 does not require a single fixed-dose tablet or a single composition. The two active ingredients may be supplied separately. Claim 8 confirms that concurrent administration is covered, but claim 7 is not limited to simultaneous dosing.
This claim creates a broader method-of-use position than the fixed-combination claims. A generic product could face risk even if it does not reproduce Lybalvi’s tablet formulation, provided the proposed treatment regimen directs the use of 10 mg samidorphan and olanzapine for schizophrenia.
Claim 10: Salt-containing pharmaceutical composition
Claim 10 covers a pharmaceutical composition containing:
- 10 mg of samidorphan on a free-base-weight basis;
- olanzapine;
- a pharmaceutically acceptable excipient; and
- samidorphan in salt form.
The claim is narrower than claim 1 because it requires a samidorphan salt. It remains broad as to the olanzapine amount, excipient identity, and dosage form.
How do claims 2 through 11 narrow the patent?
| Claim |
Limitation |
| 1 |
Daily oral schizophrenia treatment using olanzapine, 10 mg samidorphan or salt, and excipient |
| 2 |
Samidorphan is present as a pharmaceutically acceptable salt |
| 3 |
Composition is a tablet |
| 4 |
Composition contains lactose |
| 5 |
Composition contains magnesium stearate |
| 6 |
Composition contains both magnesium stearate and lactose |
| 7 |
Separate method claim requiring daily samidorphan and daily olanzapine |
| 8 |
Samidorphan and olanzapine are administered concurrently |
| 9 |
Samidorphan is present as a pharmaceutically acceptable salt |
| 10 |
Composition contains 10 mg free-base-equivalent samidorphan, olanzapine, excipient, and samidorphan salt |
| 11 |
Claim 10 composition is a tablet |
Claims 3 through 6 provide formulation fallbacks. They are narrower than claim 1 but potentially easier to prove against a product whose inactive-ingredient profile is disclosed in an ANDA, product label, or discovery record.
The presence of lactose or magnesium stearate is not required for infringement of claim 1. Those excipients matter only for the dependent claims.
What is the infringement scope of US 11,185,541?
The patent has three principal infringement pathways.
Fixed-dose tablet infringement
A generic or follow-on product is at greatest risk if it:
- contains both olanzapine and samidorphan;
- contains 10 mg of samidorphan per dosage unit;
- is administered orally once daily;
- carries a schizophrenia indication; and
- uses a tablet formulation.
Such a product could implicate claims 1, 2, 3, 10, and 11. If lactose and magnesium stearate are used, claims 4 through 6 may also apply.
Separate-product treatment infringement
A product that contains samidorphan alone may still create method-of-use risk if its labeling instructs physicians to administer 10 mg of samidorphan daily with olanzapine for schizophrenia. Claim 7 is drafted to reach that regimen even when the two drugs are not combined in one tablet.
Concurrent dosing would implicate claim 8. A salt formulation would implicate claim 9.
Induced infringement
The method claims are particularly relevant to labeling and promotional conduct. A generic manufacturer could face induced-infringement allegations if its label, prescribing information, marketing materials, dosing instructions, or clinical-support materials encourage the patented schizophrenia regimen.
A product intended only for an unpatented indication may reduce risk, but the risk depends on the actual label, distribution practices, physician instructions, and whether the patented use is practically unavoidable.
What is the Orange Book status of US 11,185,541?
US Patent No. 11,185,541 is associated with the olanzapine-samidorphan product Lybalvi. FDA Orange Book listings for combination products identify patents and use codes submitted by the approved product sponsor. The relevant patent landscape includes US 11,185,541 and related Alkermes patents directed to the combination and its therapeutic use. [3]
The Orange Book issue is important because the patent is primarily a method-of-use patent. A generic applicant may attempt to omit the patented schizophrenia indication through a section viii statement, depending on the scope of the listed use code and the remaining approved indications.
Lybalvi is also approved for depressive episodes associated with bipolar I disorder. A generic applicant could seek approval with a label that excludes schizophrenia if the FDA-approved labeling and patent use code permit that approach. That strategy would not eliminate risk if the proposed label still encourages the patented use.
When does US Patent 11,185,541 expire?
The patent is expected to expire on or about January 5, 2037, based on the patent-family term associated with the relevant Alkermes olanzapine-samidorphan filings. The precise enforceable date may be affected by terminal disclaimers, patent-term adjustment, or any applicable patent-term extension entry recorded by the USPTO or FDA.
The patent’s effective commercial life is therefore materially longer than FDA’s five-year new-chemical-entity exclusivity for samidorphan.
Exclusivity timeline
| Event |
Date or period |
| FDA approval of Lybalvi |
May 28, 2021 |
| Expected NCE exclusivity period |
Approximately through May 28, 2026 |
| Anticipated pediatric extension, if awarded |
Potentially adds six months |
| Expected US 11,185,541 expiration |
Approximately January 5, 2037 |
| Earliest practical generic entry |
Dependent on Paragraph IV litigation, settlement terms, and any later-listed patents |
FDA regulatory exclusivity and patent protection operate independently. Expiration of NCE exclusivity does not remove the patent barrier. Conversely, a successful patent challenge could allow approval before patent expiration, subject to FDA exclusivity and litigation consequences. [1][3]
What Paragraph IV challenges and litigation affect Lybalvi?
A generic applicant seeking approval before expiration of an Orange Book-listed patent may file a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed. The NDA holder may then file an action under 35 U.S.C. § 271(e)(2), triggering the statutory 30-month stay of FDA approval in the usual case.
The core litigation issues for this patent would likely include:
- Whether a proposed product contains 10 mg of samidorphan on the required free-base basis;
- Whether the proposed label induces treatment of schizophrenia;
- Whether a fixed-dose product satisfies the composition limitations;
- Whether the claims are anticipated or obvious over prior olanzapine, opioid-antagonist, and combination-treatment disclosures;
- Whether the claims satisfy written-description and enablement requirements; and
- Whether the patent’s priority chain and patent-term calculations are correct.
The claims’ reliance on a defined samidorphan dose creates a measurable infringement issue. A generic applicant may argue that a different samidorphan amount, a different therapeutic instruction, or an indication carve-out avoids the claims. That defense becomes less effective if the proposed product uses the same 10 mg dose and its labeling retains schizophrenia treatment.
No settlement term should be assumed from the patent grant or Orange Book listing alone. A generic settlement could establish a licensed entry date earlier than the January 2037 patent expiration, but the entry date would depend on the specific agreement and antitrust review record.
How strong is the patent estate for olanzapine-samidorphan?
The estate is strongest against a product that copies Lybalvi’s clinical use and dosage architecture. It is less comprehensive against alternative regimens, non-schizophrenia indications, different samidorphan doses, or products that do not instruct concurrent administration with olanzapine.
| Risk area |
Relative strength |
Reason |
| 10 mg samidorphan plus olanzapine in one tablet |
High |
Directly aligned with claims 1 and 10 |
| Samidorphan salt formulation |
High |
Explicitly covered by claims 2, 9, and 10 |
| Lactose and magnesium stearate formulation |
Moderate to high |
Covered only if those excipients are present |
| Separate samidorphan and olanzapine products |
Moderate to high |
Claim 7 reaches separate administration |
| Different samidorphan dose |
Lower |
May avoid the express 10 mg limitation |
| Bipolar-only labeling |
Moderate |
Depends on label design and actual inducement evidence |
| Samidorphan monotherapy |
Low under these claims |
Olanzapine is required |
| Olanzapine monotherapy |
None under these claims |
Samidorphan is required |
The patent is a use and combination patent, not a broad olanzapine composition-of-matter patent. Generic olanzapine products are not themselves blocked by US 11,185,541.
What formulation patents protect Lybalvi?
US 11,185,541 does not claim a narrowly defined excipient recipe in its independent claims. It requires a pharmaceutical composition and places lactose and magnesium stearate in dependent claims.
The formulation protection therefore has two layers:
- Broad composition coverage under claims 1 and 10; and
- Narrower tablet and excipient coverage under claims 3 through 6 and 11.
A formulation that replaces lactose or magnesium stearate may avoid the dependent claims but would not necessarily avoid the independent claims. The relevant question remains whether the product contains olanzapine and 10 mg of samidorphan, or a salt calculated on a free-base basis, and whether it is used for schizophrenia.
Are biosimilars relevant to this patent?
No. Samidorphan and olanzapine are small-molecule active ingredients. The relevant competitors are ANDA-based generic products, not biosimilars under the Public Health Service Act.
A future generic could seek approval for:
- The fixed-dose olanzapine-samidorphan combination;
- Samidorphan in a separate dosage form;
- Selected indications with a section viii carve-out; or
- A product with a different tablet composition or manufacturing process.
The patent does not block ordinary generic olanzapine products that do not contain samidorphan.
What generic launch scenarios exist?
Scenario 1: Full-label ANDA
A generic applicant retains schizophrenia and bipolar indications and challenges the listed patents under Paragraph IV. This creates the highest litigation exposure and the clearest path to a 30-month stay.
Scenario 2: Section viii carve-out
The applicant removes schizophrenia from the proposed labeling and seeks approval for an indication not covered by the listed use code. This may reduce infringement risk but can limit commercial value and create labeling, prescribing, and induced-infringement disputes.
Scenario 3: Formulation redesign
The applicant uses a different excipient system or tablet process. This may avoid claims 3 through 6 and 11 but does not necessarily avoid claims 1 or 10.
Scenario 4: Dose redesign
The applicant uses a samidorphan dose other than 10 mg. This may avoid the literal dose limitation, but clinical equivalence, regulatory acceptability, and commercial substitution would become more difficult.
Scenario 5: Licensed entry
A generic settles with Alkermes and receives a contractually defined launch date before January 2037. The value of such a settlement would depend on the remaining FDA exclusivity, patent term, launch restrictions, and any authorized-generic provisions.
How does US 11,185,541 compare with the broader olanzapine patent landscape?
| Patent category |
Relevance to Lybalvi |
| Original olanzapine composition patents |
Expired or no longer the principal barrier |
| Generic olanzapine patents |
Generally irrelevant unless the product uses protected manufacturing or formulation technology |
| Samidorphan composition patents |
Potentially relevant to standalone samidorphan products |
| Olanzapine-samidorphan combination patents |
Directly relevant |
| Method-of-use patents |
Relevant to schizophrenia and bipolar indications |
| Formulation patents |
Relevant to fixed-dose tablets and excipient combinations |
| Manufacturing patents |
Could affect salt formation, blending, compression, or scale-up |
| Regulatory exclusivity |
Relevant through the FDA exclusivity period, independent of patent term |
The commercial value of US 11,185,541 lies in its alignment with the approved Lybalvi regimen. It does not provide a complete monopoly over olanzapine or samidorphan individually.
What revenue exposure does the patent create?
For Alkermes, the patent protects a combination product positioned against low-cost generic olanzapine. The economic exposure is concentrated in Lybalvi sales rather than in the broader olanzapine market.
Generic entry could affect:
- Lybalvi tablet volume;
- Net price and payer rebates;
- Prescriber adoption;
- Formulary positioning;
- Conversion from generic olanzapine to the combination; and
- Potential licensing revenue from an authorized generic or settlement.
The impact would be greater for a full-label generic than for a bipolar-only or otherwise carved-out product. The patent’s long expected term gives Alkermes leverage, but the practical strength of that leverage depends on the validity of the claims, FDA exclusivity, Orange Book use codes, and the ability of a generic applicant to design around the 10 mg and schizophrenia limitations.
Key Takeaways
- US 11,185,541 covers daily oral schizophrenia treatment using olanzapine and 10 mg samidorphan.
- The patent covers both fixed-dose compositions and separate administration of the two drugs.
- Claims 1 and 10 are the principal combination-product claims.
- Claim 7 is important because it reaches separate samidorphan and olanzapine administration.
- Tablets, samidorphan salts, lactose, and magnesium stearate are addressed through dependent claims.
- The patent is directly relevant to Lybalvi.
- The expected patent expiration is approximately January 5, 2037.
- FDA NCE exclusivity is materially shorter than the patent term and is expected to expire around May 28, 2026, subject to any pediatric extension.
- A generic may pursue a Paragraph IV challenge, a section viii carve-out, a formulation redesign, a dose redesign, or a negotiated entry.
- Biosimilar competition is not relevant because both active ingredients are small molecules.
- The strongest infringement case concerns a 10 mg samidorphan/olanzapine tablet labeled for schizophrenia.
FAQs
Does US 11,185,541 cover generic olanzapine?
No. The claims require samidorphan in addition to olanzapine. Generic olanzapine alone does not practice the claimed combination.
Does the patent cover samidorphan without olanzapine?
No. The independent claims require olanzapine or require olanzapine to be administered as the antipsychotic.
Can a generic avoid the patent by removing lactose?
Possibly for claims 4 and 6, but not necessarily for claims 1, 2, 3, 10, or 11. Lactose is not required by the broadest claims.
Does using separate samidorphan and olanzapine tablets avoid infringement?
Not necessarily. Claim 7 expressly covers daily administration of samidorphan and olanzapine without requiring a single combined tablet.
Is a bipolar-only generic automatically outside the patent?
No. A bipolar-only label may reduce risk if it omits the patented schizophrenia use, but the outcome depends on the final label, use code, prescribing instructions, and evidence of induced use.
References
- U.S. Food and Drug Administration. (2021). FDA approves new treatment for adults with schizophrenia and bipolar I disorder. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Lybalvi prescribing information. Alkermes, Inc.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- United States Patent and Trademark Office. (2021). U.S. Patent No. 11,185,541, methods for treating schizophrenia.
- Alkermes plc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
